News - Novartis
The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration…
News Archive - Novartis
Review recent and past Novartis healthcare news stories, including media releases and featured information.
Novartis unveils new focused strategy, underpinned by eight …
Sep 22, 2022 · “Novartis is transforming into a ‘pure-play’ Innovative Medicines company. Our strategy is focused on five core attractive therapeutic areas, key technology platforms, and the US market, with the aim to increase value per new molecular entity from our deep pipeline”, said Vas Narasimhan, CEO of Novartis.
Novartis enters agreement to acquire Mariana Oncology, …
Basel, May 2, 2024 – Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need.
Novartis upgrades mid-term sales growth guidance, showcases its ...
Nov 28, 2023 · “Novartis has now completed its transformation into a ‘pure-play’ innovative medicines company, delivering robust increases in core margin and free cash flow, while also continuing strong operational performance.
Our next era - Novartis
Dec 4, 2023 · Our refreshed brand represents what Novartis stands for in this new era: combining science with empathy and partnership to create medicines that restore a sense of possibility for people living with disease.
Novartis
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Novartis completes acquisition of Chinook Therapeutics
Basel, August 11, 2023 — Novartis today announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.
Novartis continues strong momentum in Q3 with 10% sales …
Oct 29, 2024 · “Novartis delivered another quarter of strong operational performance in Q3, with sales up 10% and core operating income up 20%. All key growth drivers contributed to the momentum. We achieved important indications expansions for Kisqali in early breast cancer and Fabhalta in IgA nephropathy, and we completed our PSMAfore filing for Pluvicto ...
Novartis invests in early technical development capabilities for …
Sep 12, 2022 · The Novartis early-stage biologics portfolio has grown significantly in the last 15 years. It has also expanded beyond conventional monoclonal antibodies into a wide range of novel development candidates with potential to be first-in-class, best-in-class, or both, including antibody-drug conjugates and therapeutic proteins.